206 related articles for article (PubMed ID: 19445930)
1. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M; Nair S; Rui E; Lafontaine J; Almaden CD; Wells P; Krauss A
Exp Eye Res; 2009 Nov; 89(5):608-17. PubMed ID: 19445930
[TBL] [Abstract][Full Text] [Related]
2. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
[TBL] [Abstract][Full Text] [Related]
3. Corneal neovascularization and ocular irritancy responses in dogs following topical ocular administration of an EP4-prostaglandin E2 agonist.
Aguirre SA; Huang W; Prasanna G; Jessen B
Toxicol Pathol; 2009 Dec; 37(7):911-20. PubMed ID: 20008547
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
Luu KT; Zhang EY; Prasanna G; Xiang C; Anderson S; Fortner J; Vicini P
J Pharmacol Exp Ther; 2009 Nov; 331(2):627-35. PubMed ID: 19690190
[TBL] [Abstract][Full Text] [Related]
5. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
[TBL] [Abstract][Full Text] [Related]
7. Effects of prostanoid EP agonists on mouse intraocular pressure.
Saeki T; Ota T; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2201-8. PubMed ID: 19117925
[TBL] [Abstract][Full Text] [Related]
8. In-vivo activity and enzymatic hydrolysis of novel prostaglandin F2 alpha prodrugs in ocular tissues.
Woodward DF; Chan MF; Cheng-Bennett A; Wheeler LA; Chen G; Burke JA; Kharlamb A; Lai RK; Shan T
Exp Eye Res; 1996 Oct; 63(4):411-23. PubMed ID: 8944548
[TBL] [Abstract][Full Text] [Related]
9. Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes.
Sharif NA; Williams GW; Crider JY; Xu SX; Davis TL
J Ocul Pharmacol Ther; 2004 Dec; 20(6):489-508. PubMed ID: 15684809
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog.
Sharif NA; McLaughlin MA; Kelly CR; Xu S; Crider JY; Williams GW; Parker JL
J Ocul Pharmacol Ther; 2006 Oct; 22(5):291-309. PubMed ID: 17076623
[TBL] [Abstract][Full Text] [Related]
11. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
Fukano Y; Kawazu K
Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey.
Savinainen A; Prusakiewicz JJ; Oswald J; Spencer E; Lou Z; Cohen ML; Rashidzadeh H; Josiah S
Exp Eye Res; 2019 Dec; 189():107836. PubMed ID: 31626797
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide--a novel topically active carbonic anhydrase inhibitor.
Sharir M; Pierce WM; Chen D; Zimmerman TJ
Exp Eye Res; 1994 Jan; 58(1):107-16. PubMed ID: 8157096
[TBL] [Abstract][Full Text] [Related]
14. Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT.
Andrés-Guerrero V; Alarma-Estrany P; Molina-Martínez IT; Peral A; Herrero-Vanrell R; Pintor J
Exp Eye Res; 2009 Mar; 88(3):504-11. PubMed ID: 19056382
[TBL] [Abstract][Full Text] [Related]
15. Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine.
Ogidigben M; Chu TC; Potter DE
J Pharmacol Exp Ther; 1993 Nov; 267(2):822-7. PubMed ID: 7902435
[TBL] [Abstract][Full Text] [Related]
16. Ocular hypotensive and aqueous outflow-enhancing effects of AL-3037A (sodium ferri ethylenediaminetetraacetate).
Pang IH; Moll H; McLaughlin MA; Knepper PA; De Santis L; Epstein DL; Clark AF
Exp Eye Res; 2001 Dec; 73(6):815-25. PubMed ID: 11846512
[TBL] [Abstract][Full Text] [Related]
17. The 5-HT(1A)Receptor agonist 8-OH-DPAT lowers intraocular pressure in normotensive NZW rabbits.
Chidlow G; Nash MS; De Santis LM; Osborne NN
Exp Eye Res; 1999 Dec; 69(6):587-93. PubMed ID: 10620387
[TBL] [Abstract][Full Text] [Related]
18. Ocular hypotensive action of topical flunarizine in the rabbit: role of sigma 1 recognition sites.
Campana G; Bucolo C; Murari G; Spampinato S
J Pharmacol Exp Ther; 2002 Dec; 303(3):1086-94. PubMed ID: 12438531
[TBL] [Abstract][Full Text] [Related]
19. Ocular effects of topical administration of the phosphodiesterase III inhibitor milrinone in rabbits and cats.
Lee KC; Silver PJ; Bode DC; Gherezghiher T
Methods Find Exp Clin Pharmacol; 1993 Oct; 15(8):527-34. PubMed ID: 8309316
[TBL] [Abstract][Full Text] [Related]
20. Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.
Adelli GR; Bhagav P; Taskar P; Hingorani T; Pettaway S; Gul W; ElSohly MA; Repka MA; Majumdar S
Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2167-2179. PubMed ID: 28399267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
